Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: A systematic review and meta-analysis

被引：54
作者：
Galvis, Marisol Miranda [1 ,2 ]
Borges, Gabriel Alvares [2 ,3 ]
de Oliveira, Thiago Bueno [4 ]
de Toledo, Isabela Porto [3 ]
Castilho, Rogerio Moraes [2 ,5 ]
Silva Guerra, Eliete Neves [2 ,3 ]
Kowalski, Luiz Paulo [1 ,6 ,7 ]
Squarize, Cristiane Helena [2 ,5 ]
机构：
[1] Univ Campinas UNICAMP, Piracicaba Dent Sch, Oral Diag Dept, Piracicaba, Brazil
[2] Univ Michigan, Sch Dent, Lab Epithelial Biol, Dept Periodont & Oral Med, 1011N Univ Ave, Ann Arbor, MI 48109 USA
[3] Univ Brasilia, Hlth Sci Fac, Lab Oral Histopathol, Brasilia, DF, Brazil
[4] AC Camargo Canc Ctr, Clin Oncol Dept, Sao Paulo, Brazil
[5] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA
[6] AC Camargo Canc Ctr, Dept Head & Neck Surg & Otorhinolaryngol, Sao Paulo, Brazil
[7] Univ Sao Paulo, Med Sch, Head & Neck Surg Dept, Sao Paulo, Brazil
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 150卷
基金：
巴西圣保罗研究基金会;
关键词：
Head and neck squamous cell carcinoma; Immunotherapy; Human papillomavirus; Programmed death-ligand 1; Toxicity; Meta-analysis; SQUAMOUS-CELL CARCINOMA; METASTATIC HEAD; SINGLE-ARM; OPEN-LABEL; PEMBROLIZUMAB; RECURRENT; CHEMOTHERAPY; CETUXIMAB;
D O I：
10.1016/j.critrevonc.2020.102966
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Despite multiple modalities used to management of head and neck squamous cell carcinoma (HNSCC), disease control remains unsatisfactory. Immunotherapy is emerging as a novel therapeutic approach. This systematic review assesses clinical data regarding immunotherapy efficacy and safety. Methods: Data from 11 clinical trials testing immunotherapy in HNSCC were assessed. We performed the meta-analysis to correlate the overall survival (OS), response rate (RR), adverse effects, HPV status, and PD-L1 expression. Results: Immunotherapy extended OS (hazard ratio = 0.77, p < 0.0001) and RR significantly (risk ratio = 1.41, p = 0.02). Patients with HPV-positive HNSCC exhibited a better RR (risk ratio = 1.29, p = 0.24) and OS (11.5 vs. 6.3 months). PD-L1 positive tumors showed a higher OS (9.9 vs. 6.5 months). Moreover, immunotherapy caused less adverse effects than standard therapy. Conclusion: Our results indicate the benefit of immunotherapy for improving RR and OS of HNSCC patients. The benefit is higher in patients with HPV and PD-L1 positive tumors.
引用
收藏
页数：18
相关论文
共 49 条
[21]   Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck The Active8 Randomized Clinical Trial [J].
Ferris, Robert L. ;
Saba, Nabil F. ;
Gitlitz, Barbara J. ;
Haddad, Robert ;
Sukari, Ammar ;
Neupane, Prakash ;
Morris, John C. ;
Misiukiewicz, Krzysztof ;
Bauman, Julie E. ;
Fenton, Moon ;
Jimeno, Antonio ;
Adkins, Douglas R. ;
Schneider, Charles J. ;
Sacco, Assuntina G. ;
Shirai, Keisuke ;
Bowles, Daniel W. ;
Gibson, Michael ;
Nwizu, Tobenna ;
Gottardo, Raphael ;
Manjarrez, Kristi L. ;
Dietsch, Gregory N. ;
Bryan, James Kyle ;
Hershberg, Robert M. ;
Cohen, Ezra E. W. .
JAMA ONCOLOGY, 2018, 4 (11) :1583-1588
[22]   Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression [J].
Ferris, Robert L. ;
Blumenschein, George, Jr. ;
Fayette, Jerome ;
Guigay, Joel ;
Colevas, A. Dimitrios ;
Licitra, Lisa ;
Harrington, Kevin J. ;
Kasper, Stefan ;
Vokes, Everett E. ;
Even, Caroline ;
Worden, Francis ;
Saba, Nabil F. ;
Iglesias Docampo, Lara Carmen ;
Haddad, Robert ;
Rordorf, Tamara ;
Kiyota, Naomi ;
Tahara, Makoto ;
Lynch, Mark ;
Jayaprakash, Vijayvel ;
Li, Li ;
Gillison, Maura L. .
ORAL ONCOLOGY, 2018, 81 :45-51
[23]   Immunology and Immunotherapy of Head and Neck Cancer [J].
Ferris, Robert L. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29) :3293-+
[24]   Predictive biomarkers for checkpoint inhibitor-based immunotherapy [J].
Gibney, Geoffrey T. ;
Weiner, Louis M. ;
Atkins, Michael B. .
LANCET ONCOLOGY, 2016, 17 (12) :E542-E551
[25]   Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma [J].
Gillison, Maura L. ;
Chaturvedi, Anil K. ;
Anderson, William F. ;
Fakhry, Carole .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29) :3235-+
[26]   Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity [J].
Gillison, ML .
SEMINARS IN ONCOLOGY, 2004, 31 (06) :744-754
[27]   Recent advances in head and neck cancer [J].
Haddad, Robert I. ;
Shin, Dong M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (11) :1143-1154
[28]   Hallmarks of Cancer: The Next Generation [J].
Hanahan, Douglas ;
Weinberg, Robert A. .
CELL, 2011, 144 (05) :646-674
[29]   Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial [J].
Harrington, Kevin J. ;
Ferris, Robert L. ;
Blumenschein, George, Jr. ;
Colevas, A. Dimitrios ;
Fayette, Jerome ;
Licitra, Lisa ;
Kasper, Stefan ;
Even, Caroline ;
Vokes, Everett E. ;
Worden, Francis ;
Saba, Nabil F. ;
Kiyota, Naomi ;
Haddad, Robert ;
Tahara, Makoto ;
Gruenwald, Viktor ;
Shaw, James W. ;
Monga, Manish ;
Lynch, Mark ;
Taylor, Fiona ;
DeRosa, Michael ;
Morrissey, Laura ;
Cocks, Kim ;
Gillison, Maura L. ;
Guigay, Joel .
LANCET ONCOLOGY, 2017, 18 (08) :1104-1115
[30]   Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes [J].
Keck, Michaela K. ;
Zuo, Zhixiang ;
Khattri, Arun ;
Stricker, Thomas P. ;
Brown, Christopher D. ;
Imanguli, Matin ;
Rieke, Damian ;
Endhardt, Katharina ;
Fang, Petra ;
Braegelmann, Johannes ;
DeBoer, Rebecca ;
El-Dinali, Mohamed ;
Aktolga, Serdal ;
Lei, Zhengdeng ;
Tan, Patrick ;
Rozen, Steve G. ;
Salgia, Ravi ;
Weichselbaum, Ralph R. ;
Lingen, Mark W. ;
Story, Michael D. ;
Ang, K. Kian ;
Cohen, Ezra E. W. ;
White, Kevin P. ;
Vokes, Everett E. ;
Seiwert, Tanguy Y. .
CLINICAL CANCER RESEARCH, 2015, 21 (04) :870-881
12345